Spirox

Spirox Debt

The Debt of Spirox (3055.TW) as of Oct 10, 2026 is 17.78 M TWD. In the previous year, Debt was 87.93 M TWD — a change of -79.78% (lower).

Debt

17.78 MTWD

YoY

-79.78%

Last updated:

In 2025, Spirox's total debt was 17.78 M TWD, a -79.78% change from the 87.93 M TWD total debt recorded in the previous year.

The Spirox Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Debt
Date
Debt
Jan 1, 2018
9.20 M TWD
Jan 1, 2019
1.64 B TWD
Jan 1, 2020
2.47 B TWD
Jan 1, 2021
1.13 B TWD
Jan 1, 2022
474.58 M TWD
Jan 1, 2023
421.39 M TWD
Jan 1, 2024
87.93 M TWD
Jan 1, 2025
17.78 M TWD
The Spirox Debt history
YEARDebtYoY
17.78 MTWD-79.78%
87.93 MTWD-79.13%
421.39 MTWD-11.21%
474.58 MTWD-58.17%
1.13 BTWD-54.14%
2.47 BTWD+51.01%
1.64 BTWD+17,703.28%
9.20 MTWD—
0.00TWD-100.00%
92.34 MTWD+19.92%
77.00 MTWD+208.00%
25.00 MTWD—
Access this data via the Eulerpool API

Spirox Stock analysis

What does Spirox do? The Spirox Corporation is a company that was founded in 2007 and is headquartered in Menlo Park, California. The company operates in the medical technology industry and specializes in the development of products for nasal breathing. The mission of Spirox is to help people who have difficulty breathing through their nose. The company has recognized that many people have difficulty breathing through their nose due to congestion or other issues. Breathing through the mouth, however, can lead to a range of health problems such as dry mouth, sleep apnea, and respiratory infections. Therefore, Spirox has set out to develop innovative solutions to facilitate nasal breathing. Spirox's products include both implantable and non-implantable solutions. The company has a small but effective product portfolio consisting of two products: the Latera Nasal Stent and the AeroForm Nasal Stent. The Latera Nasal Stent is used to permanently open the nasal passages and facilitate breathing. The placement of the stent is a minimally invasive procedure that is typically performed on an outpatient basis. The Latera Nasal Stent is inserted and secured in the nasal wings to allow for better airflow through the nostrils. The stent is made of polydioxanone (PDO), a biocompatible polymer fiber that is absorbed by the body. Spirox's second product, the AeroForm Nasal Stent, is a non-implantable nasal stent used for temporary relief of nasal breathing. The AeroForm is a soft stent made of a flexible polymer material. It is inserted into the nasal passages and forms a gentle expansion to facilitate nasal breathing. As a company, Spirox focuses on collaboration with specialists and clinics to ensure that their products have high success rates. The company has established a partnership with the American Academy of Otolaryngology - Head and Neck Surgery (AAO-HNS) to advance scientific research and development in the nasal breathing industry. Spirox is led by experienced executives from the medical technology industry. The CEO, Duke Rohlen, has over 20 years of experience in leading medical technology companies such as Inspire Medical Systems and CV Ingenuity. The board team also includes Elektra Papadopoulos as Chair of the Board, who has worked at Hologic and Boston Scientific, among others. Although Spirox is a relatively small company, it has already received several awards. In 2017, the company was awarded the Red Herring Top 100 North America Award, which recognizes companies that are leading in the innovation industry. Overall, Spirox is an emerging company in the medical technology industry that offers innovative solutions to facilitate nasal breathing. Through collaboration with doctors and clinics and a focus on scientific research, the company aims to improve the success and effectiveness of its products. Spirox is one of the most popular companies on Eulerpool.

Debt Details

Understanding Spirox's Debt Structure

Spirox's total debt refers to the cumulative financial obligations the company owes to external parties. This can include short-term and long-term borrowings, bonds, loans, and other financial instruments. Assessing the company's debt levels is crucial for evaluating its financial health, risk profile, and ability to fund operations and expansions.

Year-to-Year Comparison

Analyzing Spirox's debt structure over the years provides insights into the firm’s financial strategy and stability. A reduction in debt can indicate financial strength and operational efficiency, while an increase may signal growth investments or potential financial challenges ahead.

Impact on Investments

Investors pay close attention to Spirox’s debt levels as they can influence the company’s risk and return profiles. Excessive debt can lead to financial strain, while moderate and well-managed debt can be a catalyst for growth and expansion, making it a critical aspect of investment evaluations.

Interpreting Debt Fluctuations

Shifts in Spirox’s debt levels can be attributed to various operational and strategic factors. An increase in debt might be geared towards funding expansion projects or enhancing operational capacity, while a decrease may indicate profit realizations or an approach to minimize financial risk and leverage.

Frequently Asked Questions about Spirox stock

Debt of Spirox is 17.78 M TWD in 2025.

Debt of Spirox changed from 87.93 M TWD to 17.78 M TWD, representing a -79.78% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Debt Spirox since 2006 – with annual values, charts, and detailed analysis.

Debt's TWD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Debt's Spirox historically and in real time.

Access this data via the Eulerpool API

Balance Sheet — Spirox

All Key Metrics — Spirox